James McArthur

James McArthur has published and patented work in the areas of immunology, gene therapy, genetic diseases, vascular biology and oncology. He has consulted for venture capital groups and biotechnology companies in diverse therapeutic areas. Prior to joining Cydan Development, Dr. McArthur was the founding employee and Chief Scientific Officer of Synovex Co, where he was responsible for all company operations and led the development of treatments for rheumatoid arthritis and fibrotic diseases. Previously, Dr. McArthur served as Vice President of Preclinical Development for Phylogix Inc, a stem cell biology company, and was the Acting Head of Research and Principal Scientist at Cell Genesys Inc. developing gene therapeutics for the treatment of genetic diseases and cancers. In addition, Dr. McArthur was a Senior Scientist at Somatix Therapy, which was acquired by Cell Genesys. Dr. McArthur received his BSc in biochemistry and PhD in molecular oncology from McGill University in Montreal and was a postdoctoral fellow at the Massachusetts Institute of Technology in Cambridge and the University of California, Berkeley. Dr. McArthur is a member of the Friedreich’s Ataxia Research Alliance (FARA) Scientific Advisory Board.